BEST UNLIMITED TURBO LONG CERTIFICATE - NOVARTIS N | Market Closed - Euronext Paris 12:30:00 2024-04-29 EDT | ||
| 7.49 EUR | -2.38% |
|
| Current month | +2.04% | ||
| 1 month | +2.04% |
Comparison chart between the derivative product and it's underlying value
End-of-day quotes
Chart
NOVARTIS AG
Latest news about NOVARTIS AG
More news
| Date | Price | Change | Volume |
|---|---|---|---|
| 24-04-29 | 7.49 | -2.38% | 109 |
| 24-04-26 | 7.673 | -2.13% | 107 |
| 24-04-25 | 7.84 | +2.27% | 109 |
| 24-04-24 | 7.666 | +0.76% | 101 |
| 24-04-23 | 7.608 | +3.62% | 111 |
Real-time Euronext Paris
Last update April 29, 2024 at 12:30 pm
More quotesStatic data
| Product type | Knock-Out without Stop Loss |
|---|---|
| Buy / Sell | CALL |
| Underlying | NOVARTIS AG |
| Issuer | 
Société Générale
|
| 93BVZ | |
| ISIN | DE000CN6GLB9 |
| Date issued | 2015-12-10 |
| Strike | 51.71 CHF |
| Maturity | Unlimited |
| Parity | 5 : 1 |
| Emission price | 4.11 € |
| Emission volume | N/A |
| Settlement | cash |
| Currency | EUR |
Technical Indicators
| Highest since issue | 8.814 € |
|---|---|
| Lowest since issue | 0.71 € |
Company Profile
Novartis AG is one of the world's leaders in the design, manufacturing, and marketing of pharmaceutical products. Net sales (excluding discontinued operations) break down by therapeutic area as follows:
- oncology (29.9%);
- immunology (17.2%);
- cardiovascular, renal and metabolic diseases (14.1%);
- neuroscience (8.9%).
The remaining net sales (29.9%) are from contract manufacturing of pharmaceutical products.
At the end of 2023, Novartis AG had 33 production sites worldwide.
Net sales are distributed geographically as follows: Europe (33%), the United States (39.5%), Asia/Africa/Australasia (20.5%), Canada and Latin America (7%).
Sector
-
Consensus: Novartis AG
Sell
Buy
Mean consensus
OUTPERFORM
Number of Analysts
20
Last Close Price
97.56
USD
Average target price
108.5
USD
Spread / Average Target
+11.20%
- Stock Market
- Certificates
- 93BVZ Certificat
